Protenus Awarded Drug Diversion Software Solutions Agreement With Premier, Inc.

Protenus, Inc., a leading provider of healthcare compliance analytics, has entered into a national group purchasing agreement with Premier, Inc. for its Drug Diversion Software Solutions. Effective from March 1, 2024, this partnership grants Premier members access to the Protenus award-winning solution under preferential pricing and terms. This move aims to enhance hospital diversion prevention and compliance programs across the United States.

Nick Culbertson, CEO and Co-founder of Protenus, expressed pride in the trust placed in their solutions by some of the nation’s largest health systems and academic medical centers. The collaboration with Premier is expected to bolster efforts to monitor and mitigate drug diversion risks within healthcare organizations. Protenus’ patented Drug Diversion Surveillance technology promises efficient workforce automation, enabling exhaustive auditing of medication use transactions to uncover potentially unnoticed inappropriate behaviors and strengthen policy compliance.

Premier, Inc. is recognized as a significant force in healthcare improvement, collaborating with a network of approximately 4,350 U.S. hospitals and 300,000 other providers. The organization strives to enhance healthcare quality and outcomes while reducing costs through data integration, analytics, and supply chain solutions among others. Premier members seeking to leverage the Protenus Drug Diversion Software Surveillance solution are advised to reference contract PPPH27PRO01 for more details.